These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 32015045)

  • 1. Case Report of Increased Exposure to Antiretrovirals following Sleeve Gastrectomy.
    Israel S; Elinav H; Elazary R; Porat D; Gibori R; Dahan A; Azran C; Horwitz E
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of veno-arterial extracorporeal oxygenation and nasogastric tube administration on the pharmacokinetic profile of abacavir, lamivudine and dolutegravir: a case report.
    Blackman AL; Heil EL; Devanathan AS; Pandit NS
    Antivir Ther; 2020; 25(2):115-119. PubMed ID: 32341207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV.
    Courlet P; Stader F; Guidi M; Alves Saldanha S; Stoeckle M; Cavassini M; Battegay M; Buclin T; Decosterd LA; Marzolini C;
    AIDS; 2020 Jan; 34(1):103-108. PubMed ID: 31490233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-Drug Interactions Between Antiretrovirals and Carbamazepine/Oxcarbazepine: A Real-Life Investigation.
    Cattaneo D; Baldelli S; Cozzi V; Fusi M; Atzori C; Micheli V; Filice C; Gervasoni C
    Ther Drug Monit; 2020 Apr; 42(2):330-334. PubMed ID: 31743292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in Serum Inflammatory Markers in Antiretroviral Therapy-Naive HIV-Infected Patients Starting Dolutegravir/Lamivudine or Dolutegravir/Lamivudine/Abacavir.
    Calza L; Legnani G; Fulgaro C; Verucchi G; Bon I; Lazzarotto T; Viale P
    J Acquir Immune Defic Syndr; 2022 Mar; 89(3):e30. PubMed ID: 34743087
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Abacavir/Dolutegravir/Lamivudine Combination Tablets in Healthy Japanese Study Participants.
    Singh RP; Adkison K; Wolstenholme A; Hopking J; Wynne B
    Clin Pharmacol Drug Dev; 2021 Sep; 10(9):985-993. PubMed ID: 34265164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection.
    Boffito M; Waters L; Cahn P; Paredes R; Koteff J; Van Wyk J; Vincent T; Demarest J; Adkison K; Quercia R
    AIDS Res Hum Retroviruses; 2020 Jan; 36(1):13-18. PubMed ID: 31507204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of Maternal and Fetal Pharmacokinetics of Dolutegravir and Raltegravir Using Physiologically Based Pharmacokinetic Modeling.
    Liu XI; Momper JD; Rakhmanina NY; Green DJ; Burckart GJ; Cressey TR; Mirochnick M; Best BM; van den Anker JN; Dallmann A
    Clin Pharmacokinet; 2020 Nov; 59(11):1433-1450. PubMed ID: 32451908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous quantification of five antiretrovirals in human tissues using ultra-high performance liquid chromatography-tandem mass spectrometry methods for therapeutic drug monitoring at the sites of action.
    West RE; Oberly PJ; Saylor AJ; Riddler SA; Nolin TD; Devanathan AS
    J Chromatogr B Analyt Technol Biomed Life Sci; 2024 Jul; 1241():124164. PubMed ID: 38823149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raltegravir-based Postnatal HIV Prophylaxis Therapy in a Neonate After in Utero Dolutegravir Exposure.
    Jacobs TG; van Aerde KJ; Colbers A; Burger DM
    Pediatr Infect Dis J; 2022 Feb; 41(2):131-132. PubMed ID: 35017453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute pancreatitis associated with dolutegravir and lamivudine/abacavir administration.
    Thompson AB; Wynn BA; O Akerele D; A Rostad C; Anderson EJ; Camacho-Gonzalez AF; Spearman P; Chakraborty R
    AIDS; 2015 Jan; 29(3):390-2. PubMed ID: 25686687
    [No Abstract]   [Full Text] [Related]  

  • 12. Intentional overdose of dolutegravir/abacavir/lamivudine (Triumeq) in a 26-year-old man.
    van Dam PM; van Geffen MW; Havenith TR; Posthouwer D
    Antivir Ther; 2018; 23(6):549-552. PubMed ID: 29533918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect?
    Cattaneo D; Minisci D; Cozzi V; Riva A; Meraviglia P; Clementi E; Galli M; Gervasoni C
    Antivir Ther; 2017; 22(4):353-356. PubMed ID: 28008867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioequivalence and Food Effect Assessment of 2 Fixed-Dose Combination Formulations of Dolutegravir and Lamivudine.
    Dumitrescu TP; Peddiraju K; Fu C; Bakshi K; Yu S; Zhang Z; Tenorio AR; Spancake C; Joshi S; Wolstenholme A; Adkison K
    Clin Pharmacol Drug Dev; 2020 Feb; 9(2):189-202. PubMed ID: 31724343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sleeve Gastrectomy in Morbidly Obese HIV Patients: Focus on Anti-retroviral Treatment Absorption After Surgery.
    Amouyal C; Buyse M; Lucas-Martini L; Hirt D; Genser L; Torcivia A; Bouillot JL; Oppert JM; Aron-Wisnewsky J
    Obes Surg; 2018 Sep; 28(9):2886-2893. PubMed ID: 29781044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Saliva as a potential matrix for evaluating pharmacologically active dolutegravir concentration in plasma.
    Yamada E; Takagi R; Moro H; Sudo K; Kato S
    PLoS One; 2021; 16(2):e0246994. PubMed ID: 33600473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dolutegravir Plus Lamivudine as First-Line Regimen in a Multicenter Cohort of HIV-1-Infected Patients: Preliminary Data from Clinical Practice.
    Ciccullo A; Baldin G; Cossu MV; Passerini M; Borghetti A; Capetti A; Di Giambenedetto S
    AIDS Res Hum Retroviruses; 2020 Jan; 36(1):4-5. PubMed ID: 31476877
    [No Abstract]   [Full Text] [Related]  

  • 18. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
    Walmsley SL; Antela A; Clumeck N; Duiculescu D; Eberhard A; Gutiérrez F; Hocqueloux L; Maggiolo F; Sandkovsky U; Granier C; Pappa K; Wynne B; Min S; Nichols G;
    N Engl J Med; 2013 Nov; 369(19):1807-18. PubMed ID: 24195548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioequivalence of a dolutegravir, abacavir, and lamivudine fixed-dose combination tablet and the effect of food.
    Weller S; Chen S; Borland J; Savina P; Wynne B; Piscitelli SC
    J Acquir Immune Defic Syndr; 2014 Aug; 66(4):393-8. PubMed ID: 24798770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increase in Body Mass Index in Children With HIV, Switched to Tenofovir Alafenamide Fumarate or Dolutegravir Containing Antiretroviral Regimens.
    Yeoh DK; Campbell AJ; Bowen AC
    Pediatr Infect Dis J; 2021 May; 40(5):e215-e216. PubMed ID: 33847305
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.